Forget whether progression-free survival (PFS) should be a surrogate endpoint in cancer trials, the FDA said as it charged the Oncologic Drug Advisory Committee (ODAC) Tuesday to look at reducing the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback